Role of mitogen-activated protein kinase kinase 4 in cancer

Oncogene

Volumn 26, Issue 22, 2007, Pages 3172-3184

  Whitmarsh, A J ^a   Davis, R J ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

JNK; MAP kinase; MKK4; p38; Tumor suppressor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

CANCER CELL; ENZYME ACTIVATION; HUMAN; IN VIVO STUDY; METASTASIS; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; MAP KINASE KINASE 4; NEOPLASMS; PROTO-ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 34248597048     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210410     Document Type: Review

References (132)

1. Adam-Stitah S, Penna L, Chambon P, Rochette-Egly C. (1999). Hyperphosphorylation of the retinoid X receptor α by activated c-Jun NH2-terminal kinase. J Biol Chem 274: 18932-18941.
2. Alt JR, Cleveland JL, Hannink M, Diehl JA. (2000). Phosphorylation- dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114.
3. Altucci L, Gronemeyer H. (2001). The promise of retinoids to fight against cancer. Nat Rev Cancer 1: 181-193.
4. Bartek J, Lukas J. (2001). Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 490: 117-122.
5. Behrens A, Jochum W, Sibilia M, Wagner EF. (2000). Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 19: 2657-2663.
6. Bierie B, Moses HL. (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520.
7. Bost F, Caron L, Vial E, Montreau N, Marchetti I, Dejong V et al. (2001). The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site. Oncogene 20: 7425-7429.
8. Bost F, McKay R, BostM, Potapova O, Dean NM, Mercola D. (1999). The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 19: 1938-1949.
9. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y et al. (2003). Mechanism of p38 MAP kinase activation in vivo. Genes Dev 17: 1969-1978.
10. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA et al. (2002). Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31: 210-215.
11. Bulavin DV, Fornace Jr AJ. (2004). p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118.
12. Bulavin DV, Higashimoto Y, Gaarde WA, Basrur V, Potapova O, Appella E et al. (2001). Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411: 102-107.
13. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW et al. (2004). Inactivation of the wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the Ink4a/Arf pathway. Nat Genet 36: 343-350.
14. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E et al. (1999). Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18: 6845-6854.
15. Buschmann T, Potapova O, Bar-Shira A, Ivanov VN, Fuchs SY, Henderson S et al. (2001). Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 21: 2743-2754.
16. 2-terminal kinase kinase in the adult and developing rat brain: an in situ hybridization study. Neuroscience 80: 147-160.
17. Casanovas O, Miro F, Estanyol JM, Itarte E, Agell N, Bachs O. (2000). Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem 275: 35091-35097.
18. Cazillis M, Bringuier AF, Delautier D, Buisine M, Bernuau D, Gespach C et al. (2004). Disruption of MKK4 signaling reveals its tumor-suppressor role in embryonic stem cells. Oncogene 23: 4735-4744.
19. Chang L, Karin M. (2001). Mammalian MAP kinase signaling cascades. Nature 410: 37-40.
20. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L et al. (2001). Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 61: 3908-3912.
21. Choi BY, Choi HS, Ko K, Cho YY, Zhu F, Kang BS et al. (2005). The tumor suppressor p16INK4a prevents cell transformation through inhibition of c-Jun phosphorylation and AP-1 activity. Nat Struct Mol Biol 12: 699-707.
22. Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL et al. (1999). Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-JunNH(2)-terminal kinases. J Clin Invest 104: 391-398.
23. Coffey ET, Hongisto V, Dickens M, Davis RJ, Courtney MJ. (2000). Dual roles for c-Jun N-terminal kinase in developmental and stress responses in cerebellar granule neurons. J Neurosci 20: 7602-7613.
24. Cuenda A. (2000). Mitogen-activated protein kinase kinase 4 (MKK4). Int J Biochem Cell Biol 32: 581-587.
25. Cui J, Han SY, Wang C, Su W, Harshyne L, Holgado-Madruga M et al. (2006). c-Jun NH2-terminal kinase 2α2 promotes the tumorigenicity of human glioblastoma cells. Cancer Res 66: 10024-10031.
26. Cunningham SC, Gallmeier E, Hucl T, Dezentje DA, Calhoun ES, Falco G et al. (2006). Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counter-weight to the evolution of tumor-suppressor loss. Cancer Res 66: 5560-5564.
27. Davis RJ. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252.
28. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace Jr AJ, Appella E et al. (2006). The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErB2-driven mammary gland tumorigenesis. Oncogene (in press).
29. Deng X, Xiao L, Lang W, Gao F, Ruvolo P, May WS, Jr. (2001). Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 276: 23681-23688.
30. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T et al. (1994). JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037.
31. Dérijard B, Raingeaud J, Barrett T, Wu I-H, Han J, Ulevitch RJ et al. (1995). Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267: 682-685.
32. Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M et al. (2003). Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112: 181-192.
33. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA, Chambers TC. (2000). Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 275: 29980-29985.
34. Finch A, Holland P, Cooper J, Saklatvala J, Kracht M. (1997). Selective activation of JNK/SAPK by interleukin-1 in rabbit liver is mediated by MKK7. FEBS Lett 418: 144-148.
35. Fleming Y, Armstrong CG, Morrice N, Paterson A, Goedert M, Cohen P. (2000). Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. Biochem J 352: 145-154.
36. Ganiatsas S, Kwee L, Fujiwara Y, Perkins A, Ikeda T, Labow MA et al. (1998). SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci USA 95: 6881-6886.
37. Gao Y, Tao J, Li MO, Chi H, Henegariu O, Kaech SM et al. (2005). JNK1 is essential for CD8+ T cell-mediated tumor immune surveillance. J Immunol 175: 5783-5789.
38. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST et al. (2006). Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol Endocrinol 20: 503-515.
39. Goloudina A, Yamaguchi H, Chervyakava DB, Appella E, Fornace Jr AJ, Bulavin DV. (2003). Regulation of human Cdc25A stability by serine phosphorylation is not sufficient to activate a S-phase checkpoint. Cell Cycle 2: 473-478.
40. Ha HY, Cho IH, Lee KW, Lee KW, Song JY, Kim KS et al. (2005). The axon guidance defect of the telencephalic commissures of the JSAP1-deficient brain was partially rescued by the transgenic expression of JIP1. Dev Biol 277: 184-199.
41. Han ZS, Enslen H, Hu X, Meng X, Wu IH, Barrett T et al. (1998). A conserved p38 mitogen-activated protein kinase pathway regulates Drosophila immunity gene expression. Mol Cell Biol 18: 3527-3539.
42. Hanks SK, Quinn AN, Hunter T. (1988). The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52.
43. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. (2002). Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32: 201-205.
44. Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD. (2006). The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 66: 2264-2270.
45. Ho DT, Bardwell J, Abdollahi M, Bardwell L. (2003). A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates. J Biol Chem 278: 32662-32672.
46. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J et al. (2002). Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 277: 43730-43734.
47. Jaeschke A, Karasarides M, Ventura J-J, Ehrhardt A, Zhang C, Flavell RA et al. (2006). JNK2 is a positive regulator of the c-Jun transcription factor. Mol Cell 23: 899-911.
48. Jiang Y, Chen C, Li Z, Guo W, Gegner JA, Lin S et al. (1996). Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta). J Biol Chem 271: 17920-17926.
49. Johnson R, Spiegelman B, Hanahan D, Wisdom R. (1996). Cellular transformation and malignancy induced by ras requires c-jun. Mol Cell Biol 16: 4504-4511.
50. Kelkar N, Delmotte MH, Weston CR, Barrett T, Sheppard BJ, Flavell RA et al. (2003). Morphogenesis of the telencephalic commissure requires scaffold protein JNK-interacting protein 3 (JIP3). Proc Natl Acad Sci USA 100: 9843-9848.
51. Kennedy NJ, Davis RJ. (2003). Role of JNK in tumor development. Cell Cycle 2: 199-201.
52. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. (2003). Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev 17: 629-637.
53. Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L et al. (2006). c-Jun N-terminal kinase is activated in non-small-cell ling cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene (in press).
54. Kim BJ, Ryu SW, Song BJ. (2006). JNK-and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 281: 21256-21265.
55. Kim GH, Park E, Han JK. (2005). The assembly of POSH-JNK regulates Xenopus anterior neural development. Dev Biol 286: 256-269.
56. Kim HL, Vander Griend DJ, Yang X, Benson DA, Dubauskas Z, Yoshida BA et al. (2001). Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res 61: 2833-2837.
57. Kishimoto H, Nakagawa K, Watanabe T, Kitagawa D, Momose H, Seo J et al. (2003). Different properties of SEK1 and MKK7 in dual phosphorylation of stress-induced activated protein kinase SAPK/JNK in embryonic stem cells. J Biol Chem 278: 16595-16601.
58. Kyriakis JM, Avruch J. (2001). Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-869.
59. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. (1996). Cyclin D1 expression is regulated positively by p42/p44MAPK and negatively by the p38/HOG-MAPK pathway. J Biol Chem 271: 20608-20616.
60. Lawler S, Cuenda A, Goedert M, Cohen P. (1997). SKK4, a novel activator of stress-activated protein kinase-1 (SAPK1/JNK). FEBS Lett 414: 153-158.
61. Lawler S, Fleming Y, Goedert M, Cohen P. (1998). Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro. Curr Biol 8: 1387-1390.
62. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S et al. (2005). Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 11: 6065-6074.
63. Lee HY, Suh YA, Robinson MJ, Clifford JL, Hong WK, Woodgett JR et al. (2000). Stress pathway activation induces phosphorylation of retinoid X receptor. J Biol Chem 275: 32193-32199.
64. Lee J-K, Hwang W-S, Lee Y-D, Han P-L. (1999). Dynamic expression of SEK1 suggests multiple roles of the gene during emryogenesis and in adult brain of mice. Mol Brain Res 66: 133-140.
65. Lei K, Davis RJ. (2003). JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 100: 2432-2437.
66. Lei K, Nimnual A, Zong WX, Kennedy NJ, Flavell RA, Thompson CB et al. (2002). The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol 22: 4929-4942.
67. Leppa S, Saffrich R, Ansorge W, Bohmann D. (1998). Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J 17: 4404-4413.
68. Lin A, Minden A, Martinetto H, Claret F-X, Lange-Carter C, Mercurio F et al. (1995). Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268: 286-290.
69. Lisnock J-M, Griffin P, Calaycay J, Frantz B, Parsons J, O'Keefe SJ et al. (2000). Activation of JNK3α1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylation JNK3α1. Biochemistry 39: 3141-3148.
70. Lopez-Aviles S, Grande M, Gonzalez M, Helgesen AL, Alemany V, Sanchez-Piris M et al. (2005). Inactivation of the CDC25 phosphatase by the stress-activated Srk1 kinase in fission yeast. Mol Cell 17: 49-59.
71. Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB. (2005). MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17: 37-48.
72. Mann KK, Padovani AMS, Guo Q, Colosimo AL, Lee HY, Kurie JM et al. (2005). Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRα phosphorylation. J Clin Invest 115: 2924-2933.
73. Matsuo Y, Amano S, Furuya M, Namiki K, Sakurai K, Nishiyama M et al. (2006). Involvement of p38alpha mitogen-activated protein kinase in lung metastasis of tumor cells. J Biol Chem 281: 36767-36775.
74. Maundrell K, Antonsson B, Magnenat E, Camps M, Muda M, Chabert C et al. (1997). Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 272: 25238-25242.
75. McDonald PH, Chow C-W, Miller WE, Laporte SA, Field ME, Lin F-T et al. (2000). arrestin-2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290: 1574-1577.
76. Mori S, Matsuzaki K, Yoshida K, Furukawa F, Tahashi Y, Yamagata H et al. (2004). TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation of the linker regions. Oncogene 23: 7416-7429.
77. Moriguchi T, Toyoshima F, Masuyama N, Hanafusa H, Gotoh Y, Nishida E. (1997). A novel SAPK/JNK kinase, MKK7, stimulated by TNFα and cellular stresses. EMBO J 16: 7045-7053.
78. Morrison DK, Davis RJ. (2003). Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 19: 91-118.
79. Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE et al. (2006). Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther 5: 630-634.
80. Nateri AS, Spencer-Dene B, Behrens A. (2005). Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 437: 281-285.
81. Nishina H, Bachmann M, Oliveiria-dos-Santos AJ, Kozieradzki I, Fischer KD, Odermatt B et al. (1997a). Impaired CD28-mediated interleukin 2 production and proliferation in stress kinase SAPK/ERK1 kinase (SEK1)/mitogen-activated protein kinase kinase 4 (MKK4)-deficient T lymphocytes. J Exp Med 186: 941-953.
82. Nishina H, Fischer KD, Radvanyi L, Shahinian A, Hakem R, Rubie EA et al. (1997b). Stress-signaling kinase SEK1 protects thymocytes from apoptosis mediated by CD95 and CD3. Nature 385: 350-353.
83. Nishina H, Vaz C, Billia P, Nghiem M, Sasaki T, De la Pompa JL et al. (1999). Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4. Development 126: 505-516.
84. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192-1197.
85. Ortega S, Malumbres M, Barbacid M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87.
86. Potapova O, Gorospe M, Bost F, Dean NM, Gaarde WA, Mercola D et al. (2000). c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 275: 24767-24775.
87. Pulverer BJ, Kyriakis JM , Avruch J, Nikolakaki E, Woodgett JR. (1991). Phosphorylation of c-Jun mediated by MAP kinases. Nature 353: 670-674.
88. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B et al. (2003). JNK-mediated BIMphosphorylation potentiates BAX-dependent apoptosis. Neuron 38: 899-914.
89. Rodrigues GA, Park M, Schlessinger J. (1997). Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J 16: 2634-2645.
90. Sabapathy K, Hochedlinger K, Nam SY, Bauer A, Karin M, Wagner EF. (2004). Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 15: 713-725.
91. Sakurai T, Maeda S, Chang L, Karin M. (2006). Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 103: 10544-10551.
92. Sanchez I, Hughes RT, Mayer BJ, Yee K, Woodgett JR, Avruch J et al. (1994). Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating the transcription factor c-Jun. Nature 372: 794-798.
93. Schutte J, Minna JD, Birrer MJ. (1989). Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci USA 86: 2257-2261.
94. Sharrocks AD, Yang S-H, Galanis A. (2000). Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem Sci 25: 448-453.
95. She QB, Chen N, Bode AM, Flavell RA, Dong Z. (2002). Deficiency of c-Jun NH(2)terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 62: 1343-1348.
96. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. (1991). Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354: 494-496.
97. Srinivas H, Juroske DM, Kalyankrishna S, Cody DD, Price RE, Xu XC et al. (2005). c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteosomal degradation of retinoic acid receptor α. Mol Cell Biol 25: 1054-1069.
98. Stark AM, Tongers K, Maass N, Mehdorn HM, Held-Feindt J. (2005). Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 131: 191-198.
99. Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH et al. (1998). Alterations in pancreatic, biliary, and breast carcinomers support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 58: 2339-2342.
100. Su GH, Song JJ, Repasky EA, Schutte M, Kern SE. (2002). Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat 19: 81.
101. Swat W, Fujikawa K, Ganiatsas S, Yang D, Xavier RJ, Harris NL et al. (1998). SEK1/MKK4 is required for maintenance of a normal peripheral lymphoid compartment but not for lymphocyte development. Immunity 8: 625-634.
102. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H et al. (2000). p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19: 6517-6526.
103. Takekawa M, Tatebayashi K, Saito H. (2005). Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell 18: 295-306.
104. Teng DH, Perry III WL, Hogan JK, Baumgard M, Bell R, Berry S et al. (1997). Human mitogen-activated protein kinase 4 as a candidate tumor suppressor. Cancer Res 57: 4177-4182.
105. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ. (2001). MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 15: 1419-1426.
106. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288: 870-874.
107. 2-terminal kinase. Proc Natl Acad Sci USA 94: 7337-7342.
108. 2-terminal kinase kinases. Mol Cell Biol 19: 1569-1581.
109. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y et al. (2004). JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23: 1889-1899.
110. Uhlirova M, Jasper H, Bohmann D. (2005). Non-cell-autonomous induction of tissue overgrowth by JNK/Ras cooperation in a Drosophila tumor model. Proc Natl Acad Sci USA 102: 13123-13128.
111. Vander Griend DJ, Kocherginsky M, Hickson JA, Stadler WM, Lin A, Rinker-Schaeffer CW. (2005). Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 65: 10984-10991.
112. Ventura JJ, Kennedy NJ, Flavell RA, Davis RJ. (2004). JNK regulates autocrine expression of TGF-β1. Mol Cell 15: 269-278.
113. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. Nature 408: 307-310.
114. Wada T, Nakagawa K, Watanabe T, Nishitai G, Seo J, Kishimoto H et al. (2001). Impaired synergistic activation of stress-activated protein kinase SAPK/JNK in mouse embryonic stem cells lacking SEK1/MKK4. J Biol Chem 276: 30892-30897.
115. Wang L, Pan Y, Dai JL. (2004). Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene 23: 5978-5985.
116. Whitmarsh AJ. (2006). The JIP family of MAP kinase scaffold proteins. Biochem Soc Trans 34: 828-832.
117. Xia Y, Wu Z, Su B, Murray B, Karin M. (1998). JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes Dev 12: 3369-3381.
118. 2-terminal kinase in oncogenic ras-induced morphologic transformation of human lung carcinoma cells. Cancer Res 60: 400-408.
119. Xin W, Yun KJ, Ricci F, Zahurak M, Qiu W, Su GH et al. (2004). MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin Cancer Res 10: 8516-8520.
120. Xiu M, Kim J, Sampson E, Huang CY, Davis RJ, Paulson KE et al. (2003). The transcriptional repressor HBP1 is a target of the p38 mitogen-activated protein kinase pathway in cell cycle regulation. Mol Cell Biol 23: 8890-8901.
121. Xu P, Yoshioka K, Yoshimura D, Tominaga Y, Nishioka T, Ito M et al. (2003a). In vitro development of mouse embryonic stem cells lacking JNK/stress-activated protein kinase-associated protein 1 (JSAP1) scaffold protein revealed its requirement during early embryonic neurogenesis. J Biol Chem 278: 48422-48433.
122. Xu Z, Kukekov NV, Greene LA. (2003b). POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J 22: 252-261.
123. Yamada SD, Hickson JA, Hrobowski Y, Vander Griend DJ, Benson D, Montag A et al. (2002). Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 62: 6717-6723.
124. Yamamoto K, Ichijo H, Korsmeyer SJ. (1999). BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-8478.
125. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, Davis RJ et al. (1997a). Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389: 865-870.
126. Yang DD, Tournier C, Wysk M, Lu HT, Xu J, Davis RJ et al. (1997b). Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci USA 94: 3004-3009.
127. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS et al. (2003). c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 9: 391-401.
128. Yashar BM, Kelley C, Yee K, Errede B, Zon LI. (1993). Novel Members of the mitogen-activated protein kinase activator family in Xenopus laevis. Mol Cell Biol 13: 5738-5748.
129. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. (1999). Mitogen-activated protein kinase kinase 4/stress-activated protein/ERK kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 59: 5483-5487.
130. Yoshida S, Fukino K, Harada H, Nagai H, Imoto I, Inazawa J et al. (2001). The c-Jun NH2-terminal kinase3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors. J Hum Genet 46: 182-187.
131. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio E, Volinia S et al. (2002). The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853-857.
132. Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G et al. (2002). The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419: 849-853.